Skip to search formSkip to main contentSkip to account menu

Flumatinib Mesylate

Known as: 4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide Mesylate 
The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

HH-GV-678
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
[Effect of flumatinib mesylate on C-MYC, HIF-1α and VEGF in U226 line].
The objective of this study was to investigate the effect of the new generation of tyrosine kinase inhibitor flumatinib mesylate… 
2013
2013
Flumatinib mesylate crystal form and preparation method and use thereof
Provided is a flumatinib mesylate crystal form C, the preparation method, pharmaceutical composition thereof and the use in the… 
2012
2012
Flumatinib mesylate crystal form and preparation method and use thereof
The invention discloses a flumatinib mesylate crystal form, and a preparation method and a use thereof. XRD characteristic peaks… 
2012
2012
Flumatinib mesylate crystal form, preparation method thereof and applications thereof
The invention discloses a flumatinib mesylate crystal form C, a preparation method thereof, a medicine composition comprising a… 
2011
2011
Method for preparing flumatinib mesylate
The invention relates to a method for preparing flumatinib mesylate. By the method for preparing flumatinib mesylate, the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)